Celyad Oncology announces EUR 500,000 private placement with Fortress at EUR 0.2 per share

Celyad SA Sponsored ADR

Celyad SA Sponsored ADR

CYAD

0.00
  • Celyad Oncology struck a EUR 500,000 private placement with a Fortress Investment Group affiliate, issuing 2,500,000 new ordinary shares.
  • Subscription price set at EUR 0.2 per share, a 15% discount to the 10-day VWAP on Euronext Brussels.
  • Closing targeted for around July 15, 2026, subject to customary conditions.
  • Fortress expected to hold about 60.71% of outstanding shares, about 68.84% of voting rights, following the issuance.
  • Proceeds earmarked for working capital; cash runway projected to extend from Q3 2026 to mid-Q2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celyad Oncology SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260713678879) on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.